Newron Pharmaceuticals S.p.A. Logo

Newron Pharmaceuticals S.p.A.

Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.

NWRN | SW

Overview

Corporate Details

ISIN(s):
IT0004147952
LEI:
8156002F8C11F80A9740
Country:
Italy
Address:
VIA MEUCCI, 3, 20091 BRESSO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the discovery and development of novel therapies for diseases of the central and peripheral nervous system. The company's research centers on creating new therapeutic classes to address significant unmet medical needs in difficult-to-treat indications, including Parkinson's disease and schizophrenia. Founded in 1999, Newron leverages its proprietary scientific research and clinical development expertise to advance drug candidates from discovery to commercialization, often through strategic partnerships with other pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 07:00
Earnings Release
Newron veroffentlicht die Ergebnisse des ersten Halbjahres 2025 und gibt ein Up…
German 16.9 KB
2025-09-16 02:00
Earnings Release
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und …
German 15.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron presents H1 2025 results and provides business update
English 24.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und g…
German 28.2 KB
2025-09-05 07:00
Regulatory News Service
Newron to present data and updates on its clinical program evaluating evenamide…
English 19.3 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron to present data and updates on its clinical program evaluating…
English 17.6 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zu…
German 14.3 KB
2025-08-12 07:00
Regulatory News Service
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
English 17.2 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
English 15.8 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
German 18.5 KB
2025-08-11 07:00
Environmental & Social Information
Newron notes the publication of new preclinical research suggesting evenamide a…
English 19.4 KB
2025-08-11 02:00
Regulatory News Service
EQS-News: Newron notes the publication of new preclinical research suggesting e…
English 17.8 KB
2025-08-11 02:00
Regulatory News Service
EQS-News: Newron verweist auf die Veröffentlichung neuer präklinischer Forschun…
German 20.9 KB
2025-05-12 07:00
Regulatory News Service
Newron gibt Genehmigung fur zulassungsrelevantes Phase-III-Entwicklungsprogram…
German 12.6 KB
2025-05-12 02:00
Regulatory News Service
EQS-Adhoc: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwickl…
German 11.3 KB

Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.